LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its third quarter of fiscal year 2019 (3QFY19) and the first nine months of fiscal year 2019 (9moFY19), the period ended May 31, 2019.
3QFY19 highlights compared with 3QFY18:
- Net revenues increased 16.2% to $9.9 million, an increase of $1.4 million over $8.6 million
- Gross profit was up 16.6% to $7.6 million, an increase of $1.1 million over $6.5 million
- SG&A was $3.1 million, an increase of 18.6% or $483,000 over $2.6 million
-
Total R&D expenditures were $1,066,000, an increase of $73,000, or 7.4% over $993,000
- In 3QFY19, $422,000 was capitalized and $643,000 was expensed
- In 3QFY18, $485,000 was capitalized and $508,000 was expensed
- Income before taxes increased 13.4% to $3.9 million, an increase of $456,000 over $3.4 million
- Net income increased 20.1% to $2.9 million, an increase of $483,000 over $2.4 million
- Diluted earnings per share increased 18.8% to $0.16 from $0.13
9moFY19 highlights compared with 9moFY18:
- Net revenues increased 12.9% to $25.9 million, an increase of $3.0 million over $23.0 million
- Gross profit was up 12.3% to $19.2 million, an increase of $2.1 million over $17.1 million
- SG&A was $8.6 million, an increase of $1.3 million, or 17.2%, over $7.4 million
-
Total R&D expenditures were $3.3 million, an increase of $274,000, or 9.2% over $3.0 million
- For 9moFY19, $1.4 million was capitalized and $1.9 million was expensed
- For 9moFY18, $1.6 million was capitalized and $1.4 million was expensed
- Income before taxes increased 3.3% to $8.6 million, an increase of $271,000 over $8.3 million
- Net income decreased 14.1% to $6.5 million, a decrease of $1.1 million from $7.6 million; this change included the one-time second-quarter tax benefit of $1.5 million reported in FY18. Without the adjustment, year-to-date income would have been up $427,000, or 7.0%
- Diluted earnings per share decreased 14.9% to $0.36 from $0.43. In FY18, the major change in diluted earnings per share came from the $1.5 million tax adjustment that accounted for an $0.08 increase in diluted earnings per share
Shawn O’Connor, chief executive officer of Simulations Plus, said: “During the quarter, we continued to make significant progress with the key initiatives we set forth at the beginning of the year. These initiatives include investments in sales and marketing strategies to take advantage of increasing adoption of modeling and simulation applications in the pharmaceutical market. In addition, we have accelerated our efforts to attract scientific talent to increase our services capacity. We have initiated efforts to increase our local presence in global markets. These efforts are beginning to show returns in our increased growth rate.”
John Kneisel, chief financial officer of Simulations Plus, added: “We continue to deliver consistent growth and profitability and maintain a strong cash position. Consolidated cash as of May 31, 2019, was $10.3 million, and $12.9 million as of July 8, 2019. Since the beginning of this fiscal year, we continued to invest in and have released new versions of all our major programs. In just the last six months, we have released new versions of GastroPlus®, ADMET Predictor®, KIWI™, DILIsym® and NAFLDsym®. We continue to expand our base of loyal customers.”
Quarterly Dividend Declared
The Company’s Board of Directors has declared a cash dividend of $0.06 per share of the Company’s common stock payable on August 1, 2019, to shareholders of record as of July 25, 2019. The declaration of any future dividends will be determined by the Board of Directors each quarter and will depend on earnings, financial condition, capital requirements, and other factors.
Investor Conference Call
The Company invites all interested persons to attend its conference call at 4:15 p.m. Eastern Time on July 10, 2019. The live webcast/teleconference will be accessible by registering here. Please dial in five to ten minutes prior to the scheduled start time. A live, listen-only teleconference will also be available by dialing (914) 614-3221, and entering access code 952-038-001. A replay of the webcast will be available at the Investors section of the Simulations Plus website following the call.
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology/toxicology models for drug-induced liver injury and nonalcoholic fatty liver disease. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical, biotechnology, and chemical agents. Our software is licensed to and used in the conduct of research by major pharmaceutical, biotechnology, chemical, consumer goods companies, and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, artificial intelligence, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for molecular property prediction from structure and physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.
Follow us on Twitter | LinkedIn
| SIMULATIONS PLUS, INC. | |||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||||
| As of | |||||
(Unaudited) |
|
(Audited) |
|||
May 31, |
|
August 31, |
|||
| ASSETS |
|
|
|
||
2019 |
|
2018 |
|||
| Current assets | |||||
| Cash and cash equivalents | $ |
10,308,125 |
$ |
9,400,701 |
|
| Accounts receivable, net of allowance for doubtful accounts of $0 | $ |
7,735,323 |
$ |
5,514,528 |
|
| Revenues in excess of billings | $ |
2,680,788 |
$ |
1,985,596 |
|
| Prepaid income taxes | $ |
- |
$ |
312,593 |
|
| Prepaid expenses and other current assets | $ |
533,772 |
$ |
610,439 |
|
| Total current assets | $ |
21,258,008 |
$ |
17,823,857 |
|
| Long-term assets | |||||
| Capitalized computer software development costs, net of accumulated amortization of $12,030,641 and $11,095,903 | $ |
4,879,484 | $ |
5,152,594 | |
| Property and equipment, net | $ |
311,841 |
$ |
335,224 |
|
| Intellectual property, net of accumulated amortization of $3,716,460 and $3,019,584 | $ |
5,258,541 |
$ |
5,905,416 |
|
| Other intangible assets net of accumulated amortization of $1,120,625 and $852,500 | $ |
3,369,375 |
$ |
3,637,500 |
|
| Goodwill | $ |
10,387,198 |
$ |
10,387,198 |
|
| Other assets | $ |
37,227 |
$ |
37,227 |
|
| Total assets | $ |
45,501,674 |
$ |
43,279,016 |
|
| LIABILITIES AND SHAREHOLDERS' EQUITY | |||||
| Current liabilities | |||||
| Accounts payable | $ |
209,085 |
$ |
351,605 |
|
| Accrued payroll and other expenses | $ |
1,409,202 |
$ |
1,152,176 |
|
| Income taxes payable | $ |
434,886 |
$ |
- |
|
| Current portion - Contracts payable | $ |
1,700,000 |
$ |
2,556,644 |
|
| Billings in excess of revenues | $ |
498,972 |
$ |
384,603 |
|
| Deferred revenue | $ |
822,159 |
$ |
381,928 |
|
| Total current liabilities | $ |
5,074,304 |
$ |
4,826,956 |
|
| Long-term liabilities | |||||
| Deferred income taxes, net | $ |
2,715,632 |
$ |
3,195,139 |
|
| Payments due under Contracts payable | $ |
1,743,357 |
$ |
3,334,296 |
|
| Total liabilities | $ |
9,533,293 |
$ |
11,356,391 |
|
| Commitments and contingencies | $ |
- |
$ |
- |
|
| Shareholders' equity | |||||
| Preferred stock, $0.001 par value | |||||
| 10,000,000 shares authorized | |||||
| no shares issued and outstanding | $ |
- |
$ |
- |
|
| Common stock, $0.001 par value | |||||
| 50,000,000 shares authorized | |||||
| 17,527,983 and 17,416,445 shares issued and outstanding | $ |
7,531 |
$ |
7,417 |
|
| Additional paid-in capital | $ |
14,813,016 |
$ |
13,453,668 |
|
| Retained earnings | $ |
21,147,834 |
$ |
18,461,540 |
|
| Total shareholders' equity | $ |
35,968,381 |
$ |
31,922,625 |
|
| Total liabilities and shareholders' equity | $ |
45,501,674 |
$ |
43,279,016 |
|
| SIMULATIONS PLUS, INC. | |||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| For the three and nine months ended May 31, 2019 and 2018 | |||||||||||||||
| (UNAUDITED) | |||||||||||||||
| Three months ended | Nine months ended | ||||||||||||||
| (Unaudited) | Unaudited | ||||||||||||||
|
2019 |
|
|
2018 |
|
|
2019 |
|
|
2018 |
|
||||
| Revenues | $ |
9,936,921 |
|
$ |
8,553,068 |
|
$ |
25,944,545 |
|
$ |
22,978,565 |
|
|||
| Cost of revenues | $ |
2,324,188 |
|
$ |
2,022,972 |
|
$ |
6,734,890 |
|
$ |
5,874,062 |
|
|||
| Gross margin | $ |
7,612,733 |
|
$ |
6,530,096 |
|
$ |
19,209,655 |
|
$ |
17,104,503 |
|
|||
| Operating expenses | |||||||||||||||
| Selling, general, and administrative | $ |
3,087,445 |
|
$ |
2,604,168 |
|
$ |
8,613,788 |
|
$ |
7,352,404 |
|
|||
| Research and development | $ |
643,255 |
|
$ |
508,356 |
|
$ |
1,896,926 |
|
$ |
1,353,503 |
|
|||
| Total operating expenses | $ |
3,730,700 |
|
$ |
3,112,524 |
|
$ |
10,510,714 |
|
$ |
8,705,907 |
|
|||
| Income from operations | $ |
3,882,033 |
|
$ |
3,417,572 |
|
$ |
8,698,941 |
|
$ |
8,398,596 |
|
|||
| Other income (expense) | |||||||||||||||
| Interest income | $ |
11,050 |
|
$ |
7,825 |
|
$ |
20,296 |
|
$ |
18,313 |
|
|||
| Interest expense | $ |
(32,702 |
) |
$ |
(38,188 |
) |
$ |
(109,078 |
) |
$ |
(114,846 |
) |
|||
| Miscellaneous income | $ |
- |
|
$ |
- |
|
$ |
- |
|
$ |
- |
|
|||
| Gain (loss) from sale of assets | $ |
- |
|
$ |
- |
|
$ |
- |
|
||||||
| Loss on currency exchange | $ |
(7,941 |
) |
$ |
9,441 |
|
$ |
(40,467 |
) |
$ |
(3,820 |
) |
|||
| Total other income (expense) | $ |
(29,593 |
) |
$ |
(20,922 |
) |
$ |
(129,249 |
) |
$ |
(100,353 |
) |
|||
| Income before provision for income taxes | $ |
3,852,440 |
|
$ |
3,396,650 |
|
$ |
8,569,692 |
|
$ |
8,298,243 |
|
|||
| Provision for income taxes | $ |
(963,734 |
) |
$ |
(990,613 |
) |
$ |
(2,045,590 |
) |
$ |
(701,415 |
) |
|||
| Net Income | $ |
2,888,706 |
|
$ |
2,406,037 |
|
$ |
6,524,102 |
|
$ |
7,596,828 |
|
|||
| Earnings per share | |||||||||||||||
| Basic | $ |
0.16 |
|
$ |
0.14 |
|
$ |
0.37 |
|
$ |
0.44 |
|
|||
| Diluted | $ |
0.16 |
|
$ |
0.13 |
|
$ |
0.36 |
|
$ |
0.43 |
|
|||
| Weighted-average common shares outstanding | |||||||||||||||
| Basic |
|
17,519,849 |
|
|
17,339,937 |
|
|
17,472,922 |
|
|
17,308,414 |
|
|||
| Diluted |
|
18,096,195 |
|
|
17,904,428 |
|
|
18,008,336 |
|
|
17,850,171 |
|
|||
